Physician profile
Rini Abraham
NPI 1285893321
$7,865.41
in general payments reported to CMS, 2019-2025
43 companies · $999 in 2025
The $999 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $853 · 2021: $712 · 2022: $1,263 · 2023: $1,249 · 2024: $1,871 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,103 · Education: $15.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,103.42 |
| Education | $15.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,419.98 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $920.60 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Qol Medical, LLC | $834.51 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $672.07 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $647.41 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $603.49 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $382.74 | 2019-2025 | |
| Lilly USA, LLC | $220.58 | 2024 | Omvoh |
| Ardelyx, INC. | $207.69 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $185.07 | 2019-2024 | Dificid, Zinplava |
| Ironwood Pharmaceuticals, INC | $172.57 | 2019-2023 | Linzess |
| Aimmune Therapeutics, INC. | $151.54 | 2024-2025 | Zenpep |
| Medical Device Business Services, INC. | $146.58 | 2024 | Linx Reflux Management System |
| E.R. Squibb & Sons, L.L.C. | $133.91 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $131.74 | 2019-2023 | Rebyota |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rini Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.